# reload+after+2024-01-20 03:46:14.866909
address1§490 Arsenal Way
address2§Suite 200
city§Watertown
state§MA
zip§02472
country§United States
phone§857-760-0900
website§https://neumoratx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
fullTimeEmployees§94
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Paul L. Berns', 'age': 56, 'title': 'Co-Founder & Executive Chairman', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 879578, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joshua  Pinto Ph.D.', 'age': 39, 'title': 'CFO & Treasurer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 876636, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Henry O. Gosebruch', 'age': 50, 'title': 'President, CEO & Director', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Carol  Suh', 'age': 34, 'title': 'Co-Founder & COO', 'yearBorn': 1989, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert Michael Poole FACP, M.D.', 'age': 66, 'title': 'Co-Founder & Advisor', 'yearBorn': 1957, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rajesh  Manchanda Ph.D.', 'age': 57, 'title': 'Chief Technical Operations Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Nicholas  Brandon Ph.D.', 'age': 49, 'title': 'Chief Scientific Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason G. Duncan', 'age': 49, 'title': 'Chief Legal Officer', 'yearBorn': 1974, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Amy  Sullivan', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. John V. W. Reynders Ph.D.', 'title': 'Chief Data Sciences Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
currency§USD
dateShortInterest§1702598400
forwardEps§-2.09
exchange§NMS
quoteType§EQUITY
shortName§Neumora Therapeutics, Inc.
longName§Neumora Therapeutics, Inc.
firstTradeDateEpochUtc§1694698200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§4525cec8-41b4-3d4c-855d-216fb57e7719
gmtOffSetMilliseconds§-18000000
targetHighPrice§26.0
targetLowPrice§13.0
targetMeanPrice§20.83
targetMedianPrice§21.0
recommendationMean§1.6
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§17.52
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
